Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02236052Phase 2Completed
Phase 2, randomised, single-blind trial in influenza, sponsored by Medicago Inc. Primary endpoints: Immunogenicity at 21 days and Solicited systemic and local reactions at 21 days. Started Jul 2014; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02236052.